New combo therapy aims to tackle tough GI cancers

NCT ID NCT07329894

Recruiting now Disease control Sponsor: Beijing GoBroad Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a two-part treatment for advanced gastrointestinal cancer: a personalized mRNA vaccine (XH001) plus immune cells trained to attack the cancer. The study will enroll 18 adults whose cancer has not responded to standard treatments. The main goal is to check safety and see if the combination can shrink tumors or help people live longer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: personalized mRNA tumor vaccine (XH001) plus tumor-specific T-cells
What this could lead to: If it works, this could point toward a new treatment option for people with advanced gastrointestinal cancer who have run out of standard options.
What could go wrong: This is a very early (Phase 1) and small (18 people) trial focused on safety, not yet proof of effectiveness. The treatment is complex and may cause side effects or not shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

digestive system cancer digestive system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTROINTESTINAL CANCER

Contacts and locations

Locations

Beijing Gobroad Hospital
RECRUITING

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.